• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate organ and marrow function.

⁃ Additional Inclusion Criteria for Dose Escalation Cohorts (Part 1a and Part 1e):

• Diagnosis of treatment-refractory advanced/metastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor with documented WNT- pathway activating mutations (WPAMs).

⁃ Additional Inclusion Criteria for Dose Escalation Cohorts (Part 1b):

• Diagnosis of treatment-refractory advanced/metastatic non-MSI-H or non-dMMR CRC.

• At least one lesion that is suitable for a core needle biopsy.

⁃ Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1c and Part 2c):

• Diagnosis of HCC with a documented WPAM (by local testing) in APC or CTNNB1. HCC that is radiographically confirmed without tissue biopsy may be enrolled with a documented CTNNB1 mutation (e.g., by ctDNA).

⁃ Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1d and Part 2d):

• Desmoid tumor (aggressive fibromatosis)

⁃ Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-1 and Part 2f-1) FOG-001 + FOLFOX + Bevacizumab:

• Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR CRC

• Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.

• One dose of mFOLFOX6 in the unresectable or metastatic setting prior to enrollment is allowed.

⁃ Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-2 and Part 2f-2): FOG-001 + Nivolumab

• Non-MSI-H or non-dMMR (by local testing) CRC with or without liver metastases.

• MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1/PD-L1

• Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible

⁃ Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-3 and Part 2f-3): FOG-001 + Trifluridine/Tipiracil + Bevacizumab

• Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC

• Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.

⁃ Additional Inclusion Criteria for Dose Expansion Cohort (Part 2a):

• Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC

⁃ Additional Inclusion Criteria for Dose Expansion Cohort (Part 2b):

• Diagnosis of advanced or metastatic solid tumors with a documented WPAM (by local testing) or equivalent evidence